Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Progress reports on immune gene therapy for stage IV renal cell cancer using lethally irradiated granulocyte-macrophage colony-stimulating factor-transduced autologous renal cancer cells
Autore:
Tani, K; Nakazaki, Y; Hase, H; Takahashi, K; Azuma, M; Ohata, J; Kitamura, R; Komine, F; Oiwa, M; Masunaga, A; Maekawa, T; Satoh, N; Adachi, D; Soda, Y; Machida, U; Endo, M; Yamazaki, T; Watari, K; Tojo, A; Yamashita, N; Tomikawa, S; Eriguchi, M; Hamada, H; Wakumoto, Y; Hanazawa, K; Okumura, K; Fujime, M; Shuin, T; Kawai, K; Akaza, H; Clift, S; Ando, D; Sherwin, S; Mulligan, R; Asano, S;
Indirizzi:
Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan Univ Tokyo Tokyo Japan 1088639 Med Sci, Minato Ku, Tokyo 1088639, Japan Juntendo Univ, Sch Med, Tokyo 113, Japan Juntendo Univ Tokyo Japan 113Juntendo Univ, Sch Med, Tokyo 113, Japan Kochi Med Sch, Nangoku, Japan Kochi Med Sch Nangoku JapanKochi Med Sch, Nangoku, Japan Univ Tsukuba, Sch Med, Tsukuba, Ibaraki 305, Japan Univ Tsukuba Tsukuba Ibaraki Japan 305 h Med, Tsukuba, Ibaraki 305, Japan Cell Genesys Inc, Foster City, CA USA Cell Genesys Inc Foster City CA USA ell Genesys Inc, Foster City, CA USA Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA Childrens Hosp Boston MA USA 02115 Hughes Med Inst, Boston, MA 02115 USA Harvard Univ, Sch Med, Dept Genet, Boston, MA USA Harvard Univ Boston MA USA ard Univ, Sch Med, Dept Genet, Boston, MA USA
Titolo Testata:
CANCER CHEMOTHERAPY AND PHARMACOLOGY
, volume: 46, anno: 2000, supplemento:, S
pagine: S73 - S76
SICI:
0344-5704(200006)46:<S73:PROIGT>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTITUMOR IMMUNITY; VACCINATION; CARCINOMA; POTENT;
Keywords:
granulocyte-macrophage colony-stimulating; factor; retrovirus vector; stage IV renal cell cancer; clinical trial; replication-competent virus;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
11
Recensione:
Indirizzi per estratti:
Indirizzo: Tani, K Univ Tokyo, Inst Med Sci, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan Univ Tokyo 4-6-1 Shirokanedai Tokyo Japan 1088639 1088639, Japan
Citazione:
K. Tani et al., "Progress reports on immune gene therapy for stage IV renal cell cancer using lethally irradiated granulocyte-macrophage colony-stimulating factor-transduced autologous renal cancer cells", CANC CHEMOT, 46, 2000, pp. S73-S76

Abstract

There is no effective treatment for patients with stage IV renal cell cancer (RCC), although the introduction of nt tv therapy is imminent. Cancer gene therapy is currently considered to be one of the most promising therapeutic modalities in the field of cancer treatment. Based on the results of animal studies, vaccination using autologous granulocyte-macrophage colony-stimulating factor-transduced renal cancer cells appears promising. Before initiating a clinical study using an ex vivo gene-transduced autologous cell vaccine-based immunogene therapy for RCC in Japan, in 1992 we initially planned a Japanese version of a clinical protocol in collaboration with a US group. In 1993, the original protocol was refined. We performed five preclinical qualification studies using RCC nephrectomy specimens from patients in1997, and the results showed that preparation of RCC cells for autologous vaccines at the Clinical Cell Technology Facility, Research Hospital of theInstitute of Medical Science, University of Tokyo, was feasible. Subsequently in August 1998, the Ministry of Health and Welfare and the Ministry of Education, Science, Culture, and Sport approved our clinical protocol. We have recruited two patients with stage IV RCC to our study so far. Here we report the background to the initiation of cancer gene therapy in Japan.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/07/20 alle ore 14:01:54